Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17256266 | INFLAMMATORY BOWEL DISEASE DIAGNOSTIC METHOD BY MEANS OF BACTERIAL METAGENOMIC ANALYSIS | December 2020 | April 2024 | Allow | 40 | 1 | 0 | No | No |
| 15733965 | METHOD OF DETECTING TARGET NUCLEIC ACID USING ROLLING CIRCLE AMPLIFICATION AND COMPOSITION FOR DETECTING TARGET NUCLEIC ACID | December 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17057936 | DENATURATION-ENHANCED DNA MUTATION TESTING FOR LIMITED BIOLOGICAL SPECIMENS | November 2020 | September 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 17056017 | Real-time fluorescence quantitative PCR detection method and kit based on metal ruthenium complex | November 2020 | January 2023 | Allow | 26 | 2 | 0 | No | No |
| 17053771 | A KIT FOR THE SPECIFIC DETECTION OF TRICHOMONAS TENAX, A SET OF PRIMERS FOR THE SPECIFIC DETECTION OF TRICHOMONAS TENAX AND A METHOD FOR THE SPECIFIC DETECTION OF TRICHOMONAS TENAX | November 2020 | July 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17053624 | TISSUE SAMPLING | November 2020 | May 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17083815 | HYBRID MULTI-STEP NUCLEIC ACID AMPLIFICATION | October 2020 | October 2023 | Abandon | 36 | 1 | 0 | No | No |
| 17045825 | METHOD FOR DETECTING VARIATION OF REFERENCE SEQUENCE IN TARGET NUCLEIC ACID REGION | October 2020 | July 2021 | Allow | 9 | 1 | 0 | No | No |
| 17061877 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | October 2020 | February 2021 | Allow | 4 | 1 | 0 | No | No |
| 17040306 | EXPERIMENTAL APPARATUS FOR BIOCHIP | September 2020 | March 2024 | Allow | 42 | 1 | 0 | No | No |
| 17018845 | Methods For Identifying Androgen Receptor Splice Variants In Subjects Having Castration Resistant Prostate Cancer | September 2020 | August 2023 | Allow | 35 | 2 | 0 | No | No |
| 17018966 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | September 2020 | January 2024 | Allow | 40 | 2 | 0 | No | No |
| 17008395 | METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING | August 2020 | April 2021 | Allow | 7 | 1 | 0 | No | No |
| 16987283 | METHOD FOR PROCESSING ROLLING CIRCLE AMPLIFICATION PRODUCTS | August 2020 | May 2022 | Allow | 21 | 1 | 0 | No | No |
| 16940517 | CELL ANALYSIS DEVICE, APPARATUS, AND CELL ANALYSIS METHOD USING SAME | July 2020 | March 2024 | Allow | 44 | 1 | 0 | No | No |
| 16934407 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | July 2020 | March 2021 | Allow | 8 | 2 | 0 | No | No |
| 16933341 | COMPOSITIONS, KITS AND METHODS FOR DETECTION OF CAMPYLOBACTER NUCLEIC ACID | July 2020 | July 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16872855 | METHOD FOR DETECTING TARGET MOLECULE | May 2020 | September 2023 | Allow | 40 | 3 | 0 | Yes | No |
| 16856924 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | April 2020 | January 2022 | Allow | 21 | 6 | 0 | No | No |
| 16831756 | DETECTION OF COLORECTAL CANCER | March 2020 | January 2021 | Allow | 9 | 1 | 1 | No | No |
| 16829133 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | March 2020 | January 2021 | Allow | 9 | 2 | 0 | No | No |
| 16649894 | Biomarker Detection From Fluid Samples | March 2020 | March 2023 | Allow | 36 | 1 | 0 | No | No |
| 16823127 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER | March 2020 | February 2021 | Allow | 11 | 1 | 0 | No | No |
| 16777700 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | January 2020 | March 2021 | Allow | 13 | 3 | 0 | No | No |
| 16752018 | NUCLEIC ACID AMPLIFICATION AND TESTING | January 2020 | May 2022 | Allow | 27 | 1 | 0 | No | No |
| 16752339 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | January 2020 | May 2021 | Allow | 16 | 3 | 0 | No | No |
| 16747833 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | January 2020 | November 2020 | Allow | 10 | 2 | 0 | No | No |
| 16743724 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | January 2020 | March 2020 | Allow | 2 | 1 | 0 | No | No |
| 16738577 | POLYMERASES ENGINEERED TO REDUCE NUCLEOTIDE-INDEPENDENT DNA BINDING | January 2020 | March 2024 | Allow | 50 | 1 | 1 | No | No |
| 16736071 | METHOD OF NUCLEIC ACID SEQUENCE DETERMINATION | January 2020 | January 2024 | Allow | 48 | 1 | 1 | No | No |
| 16736323 | METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES | January 2020 | March 2024 | Allow | 51 | 3 | 0 | Yes | No |
| 16627212 | MAGNETIC NANOPARTICLE | December 2019 | May 2024 | Abandon | 53 | 3 | 1 | No | No |
| 16622445 | METHODS AND PLATFORM FOR SCREENING AND SELECTING METABOLITES AND THEIR RECEPTORS | December 2019 | March 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16704743 | Device for the Thermal Treatment of Test Samples | December 2019 | March 2023 | Allow | 40 | 1 | 0 | No | No |
| 16619761 | METHODS FOR CHARACTERIZING LOSS OF ANTIGEN PRESENTATION | December 2019 | October 2023 | Allow | 46 | 3 | 1 | No | No |
| 16685792 | POLYNUCLEOTIDE PRIMERS AND PROBES | November 2019 | March 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16607314 | METHOD OF DETECTING MINOR BCR-ABL1 GENE | October 2019 | March 2024 | Allow | 53 | 4 | 1 | Yes | No |
| 16601540 | Identification of Traits Associated with DNA Samples Using Epigenetic-Based Patterns Detected Via Massively Parallel Sequencing | October 2019 | August 2023 | Allow | 46 | 3 | 1 | No | No |
| 16592707 | Nucleic Acid Amplification | October 2019 | April 2023 | Allow | 43 | 1 | 1 | No | No |
| 16500549 | METHOD FOR DETERMINING NUCLEIC ACID QUALITY OF BIOLOGICAL SAMPLE | October 2019 | December 2023 | Allow | 50 | 4 | 0 | Yes | No |
| 16585729 | PROCESS FOR PREPARING A BIOLOGICAL SAMPLE | September 2019 | October 2023 | Allow | 48 | 2 | 0 | Yes | No |
| 16490184 | BIOMARKER OF AGING | August 2019 | September 2022 | Allow | 37 | 1 | 1 | No | No |
| 16514814 | MULTIPLEX NUCLEIC ACID AMPLIFICATION | July 2019 | May 2023 | Allow | 46 | 4 | 0 | No | No |
| 16504065 | Methods and Devices for Performing Real Time Digital PCR | July 2019 | May 2023 | Allow | 46 | 3 | 0 | No | No |
| 16503382 | METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING | July 2019 | July 2020 | Allow | 12 | 1 | 1 | Yes | No |
| 16459689 | FABRICATION OF PATTERNED ARRAYS | July 2019 | June 2022 | Abandon | 35 | 2 | 0 | No | No |
| 16459222 | METHODS FOR PCR AND HLA TYPING USING UNPURIFIED SAMPLES | July 2019 | June 2021 | Allow | 24 | 1 | 0 | No | No |
| 16449075 | SYSTEMS AND METHODS FOR PRE-ANALYTICAL SUBSTRATE PROCESSING | June 2019 | June 2023 | Allow | 48 | 4 | 1 | Yes | No |
| 16436357 | MEASURES OF SHORT TELOMERE ABUNDANCE | June 2019 | September 2021 | Abandon | 28 | 0 | 1 | No | No |
| 16428865 | DETECTION OF COLORECTAL CANCER | May 2019 | June 2022 | Allow | 36 | 3 | 1 | No | No |
| 16501730 | Method for capturing long polynucleotides for sequencing specific gnomic regions. | May 2019 | January 2023 | Allow | 43 | 2 | 0 | Yes | No |
| 16463517 | DEVICE FOR NUCLEIC ACID AMPLIFICATION REACTION | May 2019 | December 2022 | Allow | 43 | 2 | 0 | No | No |
| 16416337 | DIGITAL MICROFLUIDICS FOR POLYMERASE CHAIN REACTION | May 2019 | September 2022 | Allow | 40 | 1 | 1 | No | No |
| 16415846 | DYNAMIC FLUX NUCLEIC ACID SEQUENCE AMPLIFICATION | May 2019 | June 2023 | Abandon | 49 | 3 | 0 | Yes | Yes |
| 16412301 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | May 2019 | November 2019 | Allow | 6 | 1 | 0 | No | No |
| 16412331 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | May 2019 | October 2019 | Allow | 5 | 1 | 0 | No | No |
| 16399103 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | April 2019 | September 2019 | Allow | 5 | 1 | 0 | No | No |
| 16399268 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | April 2019 | September 2019 | Allow | 5 | 1 | 0 | No | No |
| 16399947 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | April 2019 | May 2020 | Allow | 13 | 2 | 0 | No | No |
| 16400023 | METHODS FOR SIMULTANEOUS AMPLIFICATIONS OF TARGET LOCI | April 2019 | November 2019 | Allow | 7 | 1 | 0 | No | No |
| 16342572 | SEQUENCING AND ANALYSIS OF EXOSOME ASSOCIATED NUCLEIC ACIDS | April 2019 | March 2022 | Allow | 35 | 1 | 0 | Yes | No |
| 16380693 | INTEGRATED MOLECULAR DIAGNOSTICS SYSTEM (IMDX) AND METHOD FOR DENGUE FEVER | April 2019 | May 2022 | Allow | 37 | 2 | 1 | Yes | No |
| 16377749 | OSCILLATING AMPLIFICATION REACTION FOR NUCLEIC ACIDS | April 2019 | November 2021 | Allow | 32 | 2 | 0 | No | No |
| 16372027 | REAGENTS FOR IMPROVING PCR ACCURACY | April 2019 | June 2021 | Allow | 26 | 1 | 1 | No | No |
| 16356958 | PRESERVING GENOMIC CONNECTIVITY INFORMATION IN FRAGMENTED GENOMIC DNA SAMPLES | March 2019 | June 2021 | Allow | 27 | 1 | 1 | No | No |
| 16353636 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | March 2019 | February 2020 | Allow | 11 | 2 | 0 | No | No |
| 16352600 | DETECTION OF GENOME EDITING | March 2019 | September 2021 | Allow | 30 | 3 | 0 | No | No |
| 16288022 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | February 2019 | December 2019 | Allow | 10 | 1 | 0 | No | No |
| 16255659 | METHODS FOR DNA AND RNA EXTRACTION FROM FIXED PARAFFIN-EMBEDDED TISSUE SAMPLES | January 2019 | July 2021 | Allow | 30 | 1 | 1 | No | No |
| 16246322 | METHODS AND SYSTEMS FOR SAMPLE PROCESSING POLYNUCLEOTIDES | January 2019 | October 2019 | Allow | 9 | 1 | 0 | Yes | No |
| 16246155 | USE OF A POROUS CAPILLARY MEMBRANE FOR DETERMINING THE AMOUNT OF ROLLING CIRCLE AMPLIFICATION PRODUCTS | January 2019 | January 2021 | Allow | 24 | 1 | 0 | Yes | No |
| 16245737 | Enhanced Adaptor Ligation | January 2019 | November 2021 | Allow | 34 | 2 | 1 | No | No |
| 16245537 | SYSTEM FOR THERMAL CYCLING OF MICROFLUIDIC SAMPLES | January 2019 | January 2021 | Abandon | 25 | 1 | 0 | No | No |
| 16241778 | MULTIPHASE NUCLEIC ACID AMPLIFICATION | January 2019 | March 2021 | Allow | 27 | 2 | 0 | No | No |
| 16238753 | PROBABILITY-DIRECTED ISOLATION OF NUCLEOTIDE SEQUENCES (PINS) | January 2019 | April 2021 | Allow | 27 | 1 | 0 | No | No |
| 16222052 | METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS | December 2018 | January 2021 | Allow | 25 | 1 | 0 | No | No |
| 16192695 | METHOD FOR IDENTIFYING TARGET BIOLOGICAL MOLECULE, BEAD FOR IDENTIFYING TARGET BIOLOGICAL MOLECULE, SET OF BEADS, AND TARGET BIOLOGICAL MOLECULE IDENTIFICATION DEVICE | November 2018 | June 2021 | Abandon | 31 | 0 | 1 | No | No |
| 16301202 | METHODS OF DETECTING A MUTATED GENE BY MULTIPLEX DIGITAL PCR | November 2018 | November 2021 | Abandon | 36 | 1 | 1 | No | No |
| 16099229 | ANALYTICAL STANDARDS AND METHODS OF USING SAME | November 2018 | August 2021 | Allow | 33 | 1 | 1 | No | No |
| 16173610 | Reagent and method for rapid detection of porcine adenovirus | October 2018 | May 2021 | Allow | 30 | 1 | 1 | No | No |
| 16168349 | Processes for Point of Care Detection of DNA and RNA | October 2018 | January 2021 | Abandon | 27 | 1 | 0 | No | No |
| 16164417 | SIMULTANEOUS BACKGROUND REDUCTION AND COMPLEX STABILIZATION IN BINDING ASSAY WORKFLOWS | October 2018 | September 2021 | Allow | 35 | 1 | 1 | No | No |
| 16150815 | ASSAY FOR DETECTING HEPATITIS C VIRUS (HCV) | October 2018 | December 2020 | Allow | 27 | 0 | 1 | No | No |
| 16150001 | ASSAY FOR DETECTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) | October 2018 | June 2021 | Allow | 32 | 1 | 1 | Yes | No |
| 16140298 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI | September 2018 | August 2021 | Abandon | 35 | 1 | 1 | No | No |
| 16131524 | SPENT ENRICHMENT MEDIA FOR GROWTH OF GENE-MATCHED MICROORGANISMS | September 2018 | July 2021 | Allow | 34 | 2 | 1 | Yes | No |
| 16120072 | METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING | August 2018 | June 2019 | Allow | 10 | 1 | 0 | Yes | No |
| 16046707 | NUCLEIC ACID SEQUENCING METHODS AND SYSTEMS | July 2018 | July 2022 | Allow | 48 | 3 | 0 | No | No |
| 16041711 | Methods for the Detection of Enterovirus D68 in Complex Samples | July 2018 | January 2022 | Allow | 42 | 2 | 0 | No | No |
| 16068560 | MULTIPLE STAGE ISOTHERMAL ENZYMATIC AMPLIFICATION | July 2018 | May 2021 | Allow | 34 | 2 | 0 | No | No |
| 16013502 | ASSAY FOR DETECTION OF HUMAN PARVOVIRUS NUCLEIC ACID | June 2018 | November 2020 | Allow | 29 | 1 | 0 | No | No |
| 16013845 | DIGITAL AMPLIFICATION ASSAYS FOR GENETIC INSTABILITY | June 2018 | April 2021 | Allow | 34 | 2 | 0 | Yes | No |
| 16012667 | METHODS FOR NON-INVASIVE PRENATAL PATERNITY TESTING | June 2018 | April 2021 | Allow | 34 | 1 | 0 | Yes | No |
| 16011182 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS | June 2018 | September 2021 | Allow | 39 | 2 | 0 | No | No |
| 16062244 | Detection and Quantification of Target Nucleic Acid Sequence of a Microorganism | June 2018 | June 2021 | Abandon | 36 | 1 | 1 | No | No |
| 16007656 | POLYNUCLEIC ACID MOLECULE ENRICHMENT METHODOLOGIES | June 2018 | August 2021 | Abandon | 39 | 2 | 0 | No | No |
| 16007514 | ISOLATION OF TARGET NUCLEIC ACIDS | June 2018 | June 2021 | Allow | 36 | 3 | 0 | No | No |
| 16004714 | METHOD FOR SEQUENCING A POLYNUCLEOTIDE TEMPLATE | June 2018 | August 2020 | Allow | 27 | 1 | 0 | No | No |
| 16004337 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | June 2018 | December 2020 | Abandon | 30 | 0 | 1 | No | No |
| 15779108 | GENDER-SPECIFIC MARKERS FOR DIAGNOSING PROGNOSIS AND DETERMINING TREATMENT STRATEGY FOR RENAL CANCER PATIENTS | May 2018 | September 2021 | Allow | 40 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MUMMERT, STEPHANIE KANE.
With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MUMMERT, STEPHANIE KANE works in Art Unit 1637 and has examined 711 patent applications in our dataset. With an allowance rate of 47.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner MUMMERT, STEPHANIE KANE's allowance rate of 47.1% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MUMMERT, STEPHANIE KANE receive 2.29 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MUMMERT, STEPHANIE KANE is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +26.7% benefit to allowance rate for applications examined by MUMMERT, STEPHANIE KANE. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 19.9% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 36.4% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 70.0% of appeals filed. This is in the 56% percentile among all examiners. Of these withdrawals, 76.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 54.9% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.3% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.0% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.